Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase Ib/II Trial Evaluating the Efficacy of MK-3475 and Trastuzumab in Patients With Trastuzumab-resistant, HER2-positive Metastatic Breast Cancers

NCT02129556 is registered in ClinicalTrials.gov with ETOP IBCSG Partners Foundation as lead sponsor.

NCT NCT02129556
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02129556 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase Ib/II Trial Evaluating the Efficacy of MK-3475 and Trastuzumab in Patients With Trastuzumab-resistant, HER2-positive Metastatic Breast Cancers
Lead sponsor
ETOP IBCSG Partners Foundation
Phase
Phase 1/2
Overall status
Completed
Start date
December 31, 2014
Completion date
August 4, 2017
Enrollment
58 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic breast cancer